Champions Oncology (CSBR) Stock Price, News & Analysis

Company Overview

Champions Oncology, Inc. is a biotechnology and technology company focused on precision oncology and the development of personalized approaches to cancer treatment. The company works with pharmaceutical and biotechnology companies, academic researchers, and healthcare providers to support the discovery, development, and evaluation of cancer therapies.

Its offerings include patient-derived tumor models, including tumor avatar models, that are designed to help researchers study how individual cancers may respond to potential treatments. Champions Oncology also provides molecular profiling, bioinformatics, data analysis, and translational research services intended to connect laboratory findings with clinical development programs.

The company serves customers involved in oncology drug research and development, including organizations conducting preclinical studies and clinical trials. Its business is centered on applying patient-specific tumor data and analytics to support therapy selection, biomarker research, combination-treatment studies, and broader efforts to develop more targeted cancer treatments.

Key Stats

• Today's Range: $4.70 to $4.84
• 50-Day Range: $4.70 to $5.30
• 52-Week Range: $4.59 to $8.31
• Volume: 1,844 shs
• Average Volume: 10,597 shs
• Market Capitalization: $65.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Champions Oncology Stock Analysis - MarketRank™

Champions Oncology scored higher than 6% of companies evaluated by MarketBeat, and ranked 859th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Champions Oncology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Champions Oncology has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Champions Oncology has a P/B Ratio of 16.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.95% of the float of Champions Oncology has been sold short.

Short Interest Ratio / Days to Cover

Champions Oncology has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Champions Oncology has recently increased by 3.65%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Champions Oncology does not currently pay a dividend.

Dividend Growth

Champions Oncology does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 1.31

News Sentiment

Champions Oncology has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Champions Oncology this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Champions Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

46.30% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 9/10/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 12/15/2026
• Fiscal Year End: 4/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:CSBR
• CIK: 771856
• Web: www.championsoncology.com
• Phone: (410) 369-0365
• Fax: 410-369-0390
• Employees: 214
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): ($0.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.17 million
• Net Margins: -1.82%
• Pretax Margin: -1.47%
• Return on Equity: -25.77%
• Return on Assets: -3.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.03
• Quick Ratio: 1.03

Sales & Book Value

• Annual Sales: $59.42 million
• Price / Sales: 1.10
• Cash Flow: $0.01 per share
• Price / Cash Flow: 329.30
• Book Value: $0.29 per share
• Price / Book: 16.21

Miscellaneous

• Outstanding Shares: 13,920,000
• Free Float: 7,475,000
• Market Cap: $65.42 million
• Optionable: Optionable
• Beta: 0.44